Is Cagrilintide FDA approved?

Cagrilintide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cagrilintide administered in research settings?

In research settings, Cagrilintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cagrilintide vs GLP-1 (7-37)

Peptide Comparison

Cagrilintide vs GLP-1 (7-37)

Name: Cagrilintide vs GLP-1 (7-37) — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

Cagrilintide

AM833

Fat LossInvestigationalResearch Only

Half-life: ~7 days

19 providers listed

Full Cagrilintide profile →

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Bottom line

Cagrilintide carries stronger published evidence (Meta-analysis, 10 key studies) than GLP-1 (7-37) (RCT, 2); both are research compounds.

Quick Verdict

Cagrilintide

Evidence

Established Clinical

Half-life

~7 days

GLP-1 (7-37)

Evidence

Emerging Clinical

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cagrilintide
Further along in FDA review	Cagrilintide
More provider options (19 vs 33)	GLP-1 (7-37)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cagrilintide

GLP-1 (7-37)

Mechanism Family

Metabolic

Half-life

~7 days

—

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Research Only

Providers

19 listed

33 listed

Avail. Notes

Amylin analog by Novo Nordisk. Phase 3 as CagriSema (+ semaglutide, NCT05669755) for obesity. Not yet approved. NDA submission anticipated 2026-2027 if trials succeed.

—

Research Evidence

Cagrilintide

Established ClinicalMeta-analysis · 10 key studies · most recent 2026

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Research Citations

Cagrilintide

Meta-analysis2026 · Endocrinol Diabetes Metab

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…

RCT2026 · Lancet Diabetes Endocrinol

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…

RCT2023 · Lancet

Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…

RCT2021 · Lancet

Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…

+6 more

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

About Cagrilintide

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Research Areas

fat_loss

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cagrilintide

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

HbA1cFasting glucoseTSHCalcitoninLipaseeGFRALT/AST

Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

Cagrilintide

$13.30/mg

$9.67 – $16.77 range

12 vendors

View price index →Find providers →

GLP-1 (7-37)

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cagrilintide

19 listed

Browse directory →

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cagrilintide vs GLP-1 (7-37) — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/glp-1-7-37

https://peptidebase.io/peptides/compare/cagrilintide/glp-1-7-37 Methodology License Download JSON Download CSV